dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Sotsiaalministeerium
Sissetulev kiriAvalik

Report

Sotsiaalministeerium · 28. veebruar 2019
Viit
1.4-2/646-1
Registreeritud
28. veebruar 2019
Dokumendi liik
Sissetulev kiri
Adressaat
ReAct - Action on Antibiotic Resistance
Saabumis/saatmisviis
e-post
Funktsioon
1.4 EL otsustusprotsess ja rahvusvaheline koostöö
Sari
1.4-2 Rahvusvahelise koostöö korraldamisega seotud kirjavahetus (Arhiiviväärtuslik)
Toimik
1.4-2/2019
Vastutaja
Kärt Sõber (Sotsiaalministeerium, Kantsleri vastutusvaldkond, Terviseala asekantsleri vastutusvaldkond, Rahvatervise osakond)

Failid

  • 📎73ED01ED-5B83-4BE2-AFB5-A9BCDC820201.png
  • 📎Antimicrobial-resistance-and-sustainable-development-A-planetary-threat-but-a-financing-orphan-ReAct-DHF-December-2018.pdf2855 KB
  • 📎E-kiri.pdf79 KB
  • 📎PastedGraphic-1.png
  • 📎When the Drugs Don’t Work-Antibiotic Resistance as a Global Development Problem Feb 2019.pdf

Sisu (failidest)

development dialogue paper no.26 | december 2018 Antimicrobial resistance and sustainable development: A planetary threat but a financing orphan Planet Earth faces the very real threat of having to survive and thrive in a ‘post-antibiotic’ era in which there are few, if any, antibiotics which effectively and affordably cure infections. A world without antibiotics would necessitate radical changes in health care and farming. Despite the severity of this threat, many low- and middle-income countries struggle to identify resources for even basic activities related to antimicrobial resistance (AMR). In this context, the Dag Hammarskjöld Foundation and ReAct - Action on Antibiotic Resistance hosted a meeting to discuss how AMR could become more visible and how more funds to tackle AMR could be mobilised. Photos: Adobe Stock Images Printed by XO-Graf, Uppsala 2018 Introduction In this context, the Dag Hammarskjöld Foundation In December 2018, a meeting was convened by the and ReAct - Action on Antibiotic Resistance – hosted Dag Hammarskjöld Foundation and ReAct - Action on a meeting to discuss how AMR could become more Antibiotic Resistance - to discuss funding for the global visible and how more funds to tackle AMR could be crisis of antimicrobial resistance (AMR). Participants mobilised. came from a variety of organisations including national governments, multilateral and bilateral institutions, civil Antimicrobials are widely used in human and veterinary society organisations and academia. The meeting heard medicine and agriculture, and are then dispersed into evidence from a number of low- and middle-income the environment. The deliberations described in this countries about the extreme difficulty in identifying document are the result of the interaction of a group of funds for priority activities and finding people to act as global health actors. This means that not all aspects of AMR coordinators/focal points. AMR are fully considered: it is also important to devel- op an analysis of needs and funding options for agricul- The meeting discussed the importance of delineating ture and the environment. clear roles at global and country levels. In addition to global public goods functions, a role was identified for Neither did the meeting discuss the vital issue of research global catalytic funding to kick-start activities. AMR and development of new antimicrobials, diagnostics and funding should also be integrated into existing pro- vaccines. This is an important, but different, strand of the grammes that work in relevant areas. overall story about mobilising resources to tackle AMR. Six principles for AMR funding were identified – pay now or have to pay much more later; the form of fund- A meeting to discuss AMR financing ing mechanisms to follow the allocation of functions; A small meeting of around 20 people took place in harnessing existing funds to become more AMR- December 2018 to discuss how AMR activities might oriented; global financing channels to be visible and be financed. Participants – who attended in their accessible to countries; a health systems (not single- individual capacity – came from a variety of organisa- programme) approach; and the promotion of sustainability. tions including national governments, multilateral and This meeting identified five next steps for developing bilateral institutions, civil society organisations (CSOs) concrete proposals about how to fund AMR activities: and academia. • Explore what a global mechanism providing catalytic funding could look like. The meeting started with country presentations from • Develop stronger investment cases, nationally and Africa and Asia. A clear message emerged that there are internationally. practical difficulties finding people and money to imple- • Support country pilots to learn more about the ment AMR activities. A focal AMR-person in govern- practical challenges of implementing an AMR ment can achieve a lot if they are allocated the time to National Action Plan (NAP). devote to AMR and have sufficient authority to meet • Work with relevant international funders to and influence key actors. explore how they can adapt their work to be more AMR-oriented. A presentation based on the report Monitoring Global • Make it easier for countries to access catalytic Progress on Addressing AMR¹ reinforced the situation funds, particularly for developing AMR champions, described by countries: there is a rapid tail-off from strengthening narratives, collecting and using more the number of countries that have produced an AMR data, and supporting countries to build their own National Action Plan to the number that are making investment cases. significant progress with implementation. Antimicrobial resistance: The meeting then discussed narratives about AMR and a planetary threat but a financing orphan how AMR can be presented as part of the wider move- Planet Earth faces the very real threat of having to sur- ment for sustainable development, given its relevance to vive and thrive in a ‘post-antibiotic’ era in which there development concerns including poverty, equality and are few, if any, antibiotics which effectively and afford- nutrition. ably cure infections. A world without antibiotics would necessitate radical changes in health care and farming. The next session explored practical examples to inform Despite the severity of this threat, many low- and thinking about AMR financing. Relevant examples in- middle-income countries (LMICs) struggle to identify cluded the Green Climate Fund (which works through resources for even basic activities related to antimicrobial a number of different channels including readiness sup- resistance. port, accreditation and funds for both project prepara- development dialogue paper no. 26 | december 2018 3 tion and implementation), the Montreal Protocol be a clear go-to place for financial support. Some about ozone depletion, the Global Environment Facility respondents working for donors, on the other hand, and the Global Financing Facility related to the health were reluctant to create a new fund, partly because of of women, children and adolescents. The meeting also the political will and work required, but also because of discussed the relationship between AMR and exist- concerns about further fragmentation of global health ing funding streams, with a particular focus on the funding. The meeting also highlighted that opportunities Global Fund for AIDS, Tuberculosis (TB) and Malaria. with private sector investment such as life and health The meeting particularly benefited from some (as yet insurance services and hospital investment programmes unpublished) academic work based on a number of key should be further explored. informant interviews. The preliminary results showed how people’s opinions about the best way to fund AMR Break-out groups were set the challenge of identifying were greatly influenced by where they were based. Most tangible financing options. A clear resulting message respondents based in LMICs favoured some sort of was that it is important to think of different solutions at AMR-dedicated global funding stream because it would different levels – what needs to happen in countries and what is the role of the global level? Frequently encountered barriers to implementing AMR activities in LMICs • It is vital to have individuals with a designated role in moving AMR forward: AMR focal points. They cannot be effective if they are over-burdened with other non-AMR tasks or if the focal point role carries no authority. • There is no go-to place for funds for the early stage of NAP implementation: easily accessible funds for initiating activities and for pilots would be very helpful. • For countries, an effective AMR governance structure and a costed NAP are necessary but not sufficient: there needs to be a source of catalytic funding. We need a convincing story to attract funds • Antibiotics have become a substitute for good In the context of policymaking and financing, a ‘narra- quality health care. We must raise standards in tive’ is a concise way of describing an issue and why it is basic infection prevention. important. The meeting discussed AMR narratives: how • It is impossible to deliver Universal Health AMR can be presented as part of the wider movement Coverage (UHC) without ensuring access to for sustainable development and AMR’s relevance to affordable, quality antibiotics. AMR will make development concerns including ending poverty and provision of basic essential health services more hunger, good health, clean water, the environment and expensive and therefore delay UHC. responsible production and consumption. • Health insurance companies frequently fund activities related to better exercise and diet because Developing AMR narratives is difficult but vital. AMR these investments save money over time. The can be managed, but not completely solved; we must ac- same should apply to AMR: insurance companies knowledge that insufficient access to antibiotics in many should demand high standards of drug stewardship countries occurs at the same time as some populations and infection prevention and control. use antibiotics to excess. We need to communicate the • The expansion of AMR is a huge risk because importance of urgently tackling AMR and that if we do it threatens recent gains in key areas of global health, not do this there will be catastrophic impacts on people’s including maternal and neonatal health, TB and health and diets, with food and medicines becoming HIV. more expensive and effective antimicrobials becoming • The Global Health Security Agenda was scarcer. launched in 2014 and has quickly attracted consid- erable attention and funding. Its aim is to create a Examples of AMR narratives connected to major global world safe from infectious disease threats, including health issues include: by elevating global health security to be a priority of national leaders. AMR is an important part of this agenda. 4 development dialogue paper no. 26 | december 2018 We need to make sure that AMR narratives are widely Each phase is different in every country and requires heard, as this will increase the prospects of mobilising different kinds of support – technical and financial – funding. To do this we need to identify and educate from the global and regional levels. CSOs can play a AMR champions. pivotal role in many situations, including mobilising a range of stakeholders and monitoring for accountability. Narratives need to be backed up by credible data. There The nature of AMR means it is important to look at is a great deal to be done about this in the field of AMR governance and implementation of the NAP AMR. Existing data needs to be used to make as holistically. Tackling AMR requires change within the effective a case as possible now; the narrative can be health system in terms of how it manages drugs and strengthened over time as data improves. Narratives deals with infection: piecemeal funding of specific need to be based on information about: actions can help, but are not a substitute for embedded, • the prevalence and types of AMR (where is it a system-wide change. problem and relating to which particular drugs?), • illness and deaths which can be attributed to AMR, For countries without a completed NAP, the challenge • the cost of tackling AMR and what can be achieved. is one of advocacy and practical technical support. What steps are needed to start the development of a NAP An investment case is a particular kind of narrative with appropriate local ownership and involvement? which describes alternative courses of action and their Countries vary in terms of how pro-active CSOs and implications. Investment cases about AMR – at the development partners need to be. hospital, national, regional and global levels – need to be developed and strengthened. Many countries are stuck at the first steps of imple- menting NAPs (Phase 2). It is challenging to develop an Investment cases should specify what can be done about AMR Committee that functions effectively in relation AMR, how much that would cost and what the im- to multiple sectors and which operates through clear pact would be. This would then be compared with the action points with accountability for implementation. negative impacts (the costs) of doing nothing about Full-time staff in an AMR Secretariat – or at least desig- AMR. This work would build on the World Bank’s 2017 nated sectoral focal points – are vital at this stage. simulations, which found that by 2050 annual global gross domestic product (GDP) could fall by as much as When countries actually start implementing priority 3.8%, relative to a base-case scenario where no AMR activities described in the NAP (Phase 3), much of the effects were incorporated into the model. The GDP focus needs to be on working with existing players to shortfall would exceed US$ 3.4 trillion annually after make their activities more AMR-oriented. This phase 2030. Losses would disproportionately affect low-in- may require some catalytic funding, but over time more come countries. Investment in AMR was judged to have and more funding will come from in-country sources. exceptionally high economic and health yields, with a potential 88% return if 75% of AMR’s negative effects The meeting did not discuss Phase 4 in any detail. At were avoided.² this stage, the vast majority of funding is country-based, with a relatively small role for ongoing global functions Phases of implementation such as data analysis and information sharing. By 2018, 112 countries had a National Action Plan for AMR, with a further 67 countries in the process of developing a NAP. However only about 12% of Money for what activities, delivered countries with NAPs had engaged all the relevant and funded by whom? sectors and identified funding.³ It can be helpful to Whilst exploring relevant examples and discussing think about how countries move from developing a during break-out sessions, meeting participants realised NAP, through early start-up activities, then scaling up that it was important to be clear on what AMR implementation and moving towards sustainability. activities were being talked about and the respective roles of countries and the global level. Detailed There are four identifiable phases: discussions resulted in the allocation of roles described • Situation analysis and an approved NAP (Phase 1) in Boxes 1 and 2. • Readiness to implement the NAP – ie establishing the structures and people that can mobilise ‘Form follows function’ is the notion that it is import- resources, prioritise activities and stimulate ant to be clear about who does what. In this context, implementation (Phase 2) it means that the design of a funding stream depends • Implementation of key priorities (Phase 3) on what activities are to be supported and who is best • Broader implementation with sustainable financing placed to deliver these activities. (Phase 4) development dialogue paper no. 26 | december 2018 5 Box 1: AMR activities - global functions Global public good • Data collection, analysis, interpretation and sharing. (Surveillance of resistance, the disease burden caused by AMR, antimicrobial use). • Analysis of country progress with AMR to enable countries to compare themselves with others. Collect and share best practices and success stories. • Guidelines and minimum standards, with accompanying technical support. • Coordination - Efficient, streamlined implementation of the above functions (key roles for the World Health Organization (WHO), Food and Agriculture Organization (FAO), World Organisation for Animal Health (OIE), UN Environment Programme (UN Environment)). - Working with development partners which support relevant activities in countries: integration of AMR into existing funding portfolios at global level. Development partners to deliver strong, consistent messages about the importance of AMR activities and how they can be integrated into existing work. Catalytic function • Catalytic funding, advocacy and technical support for countries to move through the AMR Phases described above: - developing a NAP, - creating governance structures that enable NAP implementation, - understanding how to integrate AMR into existing programmes/initiatives and starting key workstreams within the NAP, - moving towards sustainability. Some areas of work, notably collecting and using data, now time to bring these ideas together in the context of are both global and country functions. It is a national AMR financing. function to collect data according to the country’s own needs and also to contribute information to meet global For countries that are yet to develop a NAP or are in requirements. It is a global responsibility to collect and the early steps of implementation (Phases 1-3), the use this data, and to support countries which are strug- global functions related to data, coordination, guidelines gling to collect it. and overviews of progress are all relevant. But there is also another global function: to be catalytic. ‘Catalytic’ in Different country phases require this sense means enabling a process to start and moving different kinds of global support it towards being implemented with a country’s own Having described global functions and identified resources. For Phase 1 countries, much of the catalytic phases of NAP development and implementation, it is role is advocacy and technical support about how to 6 development dialogue paper no. 26 | december 2018 Box 2: AMR activities - country functions The list below illustrates the range of work which needs to happen in countries. However, the list of ‘AMR activities’ is so long and wide-reaching that it can be more useful to think of AMR activities as a crucial element of the health system as a whole. From this angle, the challenge is to integrate AMR-action into the overall planning and governance of the health sector, into every health facility and programme. • Foster political will and decisiveness, generating and using data to strengthen the case for action on AMR. • Develop a NAP that is formally approved. • Establish a governance structure that can enable and monitor implementation and hold actors accountable. • Map who is already doing what and with what resources: government, technical institu- tions, insurers, health providers, manufacturers, development partners, CSOs. • Work with actors in relevant areas to encourage them to work in an AMR-oriented way: this capitalises on existing in-country activities. Relevant areas include: – AMR specific: antimicrobial stewardship (standard treatment guidelines, use, quality, retail conditions); Infection Prevention and Control. – AMR sensitive: integrate AMR into existing national programmes/institutions including primary care, hospitals, laboratories, HIV, TB, malaria, maternal and child health, water and sanitation (WASH), immunisation, global health security, health worker education and essential medicines programmes. • Allocate responsibility for AMR-specific activities which may not have an obvious ‘home’, such as awareness and behavioural change interventions. • Human resources: understand the skills and numbers of people required and plan how to make these available. address AMR. In Phase 2, a key global role is to support countries is mostly about data, technical standards and the development of effective AMR governance sharing information. structures, as well as some financing to kick-start imple- mentation. Phase 3 countries will also require catalytic financing to expand the proportion of activities from the NAP which are functioning well. A country that is implementing and sustainably funding its NAP (Phase 4) has largely integrated its AMR work into national processes: the AMR response has been institutionalised and many activities will be embedded in ongoing national programmes. The global role in such development dialogue paper no. 26 | december 2018 7 Figure 1: AMR financing functions during different phases of the National Action Plan Global funding for core global functions Phase 1 Phase 2 Phase 3 Phase 4 Phases of AMR work Catalytic global funding In-country funding - sustained Figure 1 depicts how the composition of AMR funding • Coordination and information-sharing. is likely to change over time as a country develops its • Initiate country pilots:This could be in specific NAP and proceeds with implementation. The pink line technical areas, but would ideally support the wider shows the role of global catalytic funds: the amount of governance function of working with multiple money required for this is likely to be highest in Phase 3 actors to make sure AMR work is happening in when a country moves from concerns about governance their specific area of work. Share information about and writing the NAP towards starting to implement experiences. activities. The arrow in teal shows that there is also a • Engage with regional institutions and fairly stable global public good element which requires programmes: All levels – global, regional and ongoing financial support. The purple line shows national – have a role to play in ensuring that AMR in-country funding, mostly from government and the activities are integrated wherever relevant and in as private sector: this funding grows over time until it can consistent and cohesive a way as possible. eventually plateau. • Work in areas where there are economies of scale, skills shortages or other compel- The role of regions ling technical reasons to work on behalf of a A focus on national and global functions does not cap- number of countries. Examples could include ture the whole picture – there is also the regional level, specialist procurement, quality control of laborato- involving regional bodies such as the African Union and ries or analysis of drug efficacy. the Association of Southeast Asian Nations (ASEAN). There is great variation amongst regions in terms of ‘Regions’ refers to countries grouped geographically. their capacity, institutional set-up and the number and The same list of functions could also apply to a group sizes of constituent countries. of countries from different regions that are at a similar place in the journey from Phase 1 to Phase 4. Nevertheless, it is possible to identify some potential functions for regions: • Leadership: Be aware of when countries are stuck on Phase 1 or Phase 2. Identify areas of common concern amongst countries which would benefit from a collective solution. 8 development dialogue paper no. 26 | december 2018 Box 3: Funding sources in addition to governments and donors There is a risk that financing discussions focus disproportionately on funding from governments and from donors (globally, donors contribute less than 1% of total health expenditure).⁴ In many countries out-of-pocket spending and private sector investment such as insurance are also very important. One of the country functions specified in Box 2 is to have a dialogue ‘with actors in relevant areas to encourage them to work in an AMR-oriented way’. The nature of the dialogue – and its participants – varies according to the funding source. Out-of-pocket expenditure. Out-of-pocket expenditure on antimicrobials typically happens when there are gaps in public sector services and essential medicine supplies and when consumers buy drugs from unregulated sellers. This is an extremely difficult issue to tackle, requiring a blend of education, regulation and enforcement. Nevertheless, well- designed and widely-disseminated messages to consumers about the quality of antibiotics and appropriate usage, for example, could help to shift this existing spending away from unwittingly harmful purchases of antimicrobials. If this issue is not addressed, a significant part of overall health sector activity does not become more AMR-oriented. Universal Health Coverage is important here, as one of its elements is to reduce reliance on out-of-pocket spending. Insurance. Spend-to-save arguments can make sense to insurers. AMR cases cost more to treat than non-resistant cases; preventing infections and resistance can make financial sense. Principles for AMR financing Given its complexity and the multiple stakeholders So far this document has discussed the importance of involved, coordination of AMR funding is vital: part explaining why AMR is important; the shortage of of efficient financing is to devise effective coordination money to tackle AMR; the fact that a lot of funds are mechanisms at various levels. The need for coordination already spent on AMR-sensitive activities; and the need is made all the more apparent when the reader is re- to be clear about which AMR activities are best dealt minded that this paper focuses on the health sector, and with at the national, regional and global levels. Taking that equivalent attention needs to be paid to financing all these considerations together, it should be clear that for animal health and the environment. It makes sense ‘funding AMR’ must happen in a variety of ways for to think in terms of starting with funding mechanisms different activities and at different levels: the challenge for animal health and the environment that are sepa- is to describe a bundle of financing mechanisms that rate from health funding channels because this is how combine to address AMR. The word ‘bundle’ is used governments work and because different technical skills deliberately – this is not about a neat set of activities are required. that fit together like a jigsaw. We need to think in terms of tackling AMR on multiple fronts through multiple channels. The meeting did not go into great detail about specific funding mechanisms, but it did identify a number of principles for AMR funding (see Box 4). development dialogue paper no. 26 | december 2018 9 Box 4: Principles for AMR funding • The choice is to pay now or to have to pay much more later: this case needs to be made persuasively to a variety of audiences. • The form of funding mechanisms should follow the allocation of functions. Boxes 1 and 2 described global and country roles: funding should promote this division of labour. • Much can be done to harness existing funds to become more AMR-oriented. We cannot just assume that international and national players will do this: there is a need for accountability mechanisms for being AMR-responsible. • Global financing channels should be clearly visible and accessible for countries. • Mechanisms should promote a health systems approach, rather than fragmentation. • The design of financing mechanisms should promote long-term sustainability. Some mechanisms can be explicitly short-term and catalytic. Next steps • Is it possible for a large fund and its associated This meeting was an early step in developing concrete bureaucracy to maintain an effective focus on being proposals about how to fund AMR activities. A lot of catalytic? time was spent on thinking through the implications of the global/regional/country division of labour and 2. Develop stronger investment cases, nationally mapping out how patterns of funding might change and internationally. over time. There was considerable interest in mecha- • Develop tools to help countries build their own nisms such as the Green Climate Fund and a desire to investment cases about AMR. understand more about relevant examples. The discus- • Ensure that appropriate technical capacity exists and sions were inevitably inconclusive, but five clear areas for make it available to support countries with this.⁶ further work emerged. • Use existing data and improve data availability, develop convincing evidence-based narratives. 1. Explore what a global mechanism providing • Stress the implications of doing nothing or doing catalytic funding could look like. Dialogues with too little – this is impact in terms of human health, governments, multilateral and bilateral agencies, founda- food supplies, poverty and inequality. tions and others can build up a picture of what is desir- • Emphasise the real risk that past improvements in able and realistic. There are many questions to explore, health, wealth and nutrition could be reversed if the including: world had to cope without effective antibiotics. • Should there be an AMR-specific, stand-alone funding channel? Or could a mechanism be housed 3. Support a small number of country pilots within an existing institution? Which one? One or to learn more about the practical challenges in more UN agencies? The Global Fund? Or is there implementing a NAP. This is about improving our a need for a new set-up, for example a multi-partner understanding of what happens during Phase 3, when trust fund? activities are beginning but are not yet institutionalised • How much new global donor money is required and sustainable. and how much is about re-allocating existing funding? A crucial aspect of this is enabling one or more AMR • Is there an appetite for developing a new funding coordinators at the country level to have time to work source, such as a tax or levy? A relevant example to on the many strands of AMR work, with appropriate explore is UNITAID, whose single main source of technical support and encouragement where necessary. income is an airline ticket levy in approximately What are the real-life experiences in harnessing exist- ten countries.⁵ ing activities to become more AMR-oriented? What • Could results-based financing be incorporated? strategies work? What conversations need to be had and • Could one mechanism be designed to provide funds what partnerships tend to be successful? What external to a variety of types of organisations, including support in terms of technical assistance and finances is governments and CSOs? required? Where do resources come from in practice? 10 development dialogue paper no. 26 | december 2018 4. Work with relevant international funders to explore how they can adapt their work to be more AMR-oriented. The Global Fund is one obvious funder, as is the Global Alliance for Vaccines and Immunization (Gavi), though this may be more in the area of product development and procurement. Key issues to explore with the Global Fund are the extent to which AMR-specific activities might success- fully be included in proposals and how to encourage this, as well as ways to maximise work on infection prevention and control and antimicrobial stewardship. Would the mandate of the Global Fund need to be extended to do this in a significant way, or is the current mandate (including support for health systems strength- ening) adequate? 5. Make it easier for countries to access catalytic funds in the short term and promote specific priorities for catalytic funding. Countries face a very practical challenge in knowing where to go to access funds to start the process of implementing a NAP. There are a number of things that could be done to improve this, ranging from basic steps such as compiling information about possible funding sources for AMR, to developing the global mechanism described above as quickly as possible, perhaps with an interim arrangement in place to speed up access to funds. In terms of priorities for this funding, four areas were identified. These are all catalytic activities, in that they are about stimulating or enabling further substantive work on AMR: • Continue to identify and work with a wide variety of champions to help spread understanding about AMR. • Develop and improve narratives and related devices such as an ‘AMR clock’. • Collect and use more data, including sentinel point prevalence studies and estimates of AMR-attributable mortality. This is to comple- ment existing data collection funded by, amongst others, national governments and the Fleming Fund. • Develop a tool to help countries build their own investment cases. Ensure that appropriate technical capacity exists and make it available to countries. development dialogue paper no. 26 | december 2018 11 Endnotes ¹WHO/FAO/OIE, ‘Monitoring Global Progress on Addressing AMR’, ⁴IHME, ‘Financing Global Health’, (report, IHME, 2017). http:// (report, WHO/FAO/OIE, 2018). www.healthdata.org/sites/default/files/files/policy_report/2018/ https://www.who.int/antimicrobial-resistance/publications/Analysis- IHME_FGH_2017_fullreport.pdf report-of-AMR-country-se/en/ ⁵World Bank and GAVI Alliance, ‘Immunization Financing Toolkit: ²World Bank, ‘Drug-Resistant Infections: A Threat to Our Economic Brief 18 Innovative Financing – Airline Ticket Tax’, (toolkit, World Future’, (report, World Bank, 2017). Bank and GAVI Alliance, 2010). https://www.who.int/immunization/ http://documents.worldbank.org/curated/en/323311493396993758/ programmes_systems/financing/tools/final_toolkit_2011.pdf ?ua=1 pdf/114679-REVISED-v2-Drug-Resistant-Infections-Final-Report.pdf ⁶The collaborative Project on Medicine Prices and Availability by ³WHO/FAO/OIE ‘Monitoring Global Progress on Addressing AMR’, WHO and the NGO Health Action International is a potentially useful (report, WHO/FAO/OIE, 2018). model for how this could work. This paper was prepared by the Dag Hammarskjöld Foundation and ReAct. It was edited by Catriona Waddington, based on contributions from the meeting participants. It builds on background documents provided to the participants and processes and synthesises discussions. All contributors spoke in their personal capacities and not on behalf of the organisations or governments to which they belong. Participants were: Karin Abbor-Svensson, Dag Hammarskjöld Foundation Håkan Björkman, UNDP Otto Cars, ReAct Sujith Chandy, ReAct Yoke Ling Chee (by video-conference), Third World Network Carlos Correa, South Centre Kim Faure, Mediclinic South Africa Tracie Muraya, ReAct Anders Nordström, Swedish Ministry of Foreign Affairs Ejike Nwokoro, University of Bergen Trygve Ottersen, Norwegian Institute of Public Health Charles “Ok” Pannenborg, former Chief Adviser and Director, World Bank Stefan Swartling Peterson, UNICEF Mengying Ren, ReAct Andreas Sandgren, ReAct Anthony So, ReAct Liz Tayler, WHO Göran Tomson, Karolinska Institutet Maarten van der Heijden, ReAct Catriona Waddington, Mott MacDonald This paper was prepared by the Dag Hammarskjöld Foundation and ReAct ReAct - Action on Antibiotic Resistance is an independent global network for concerted action on antibiotic resistance www.reactgroup.org The Development Dialogue paper series is published by the Dag Hammarskjöld Foundation and aims to provide analysis and practical recommendations on important development issues. www.daghammarskjold.se [email protected] Saatja: Anna Zorzet <[email protected]> Saadetud: 28.02.2019 14:34 Adressaat: Anna Zorzet <[email protected]> Koopia: Andreas Sandgren <[email protected]>; Otto Cars <[email protected]> Teema: New report on Antibiotic Resistance and Sustainable Development Dear Minister of Health,It is our great pleasure to share with you a new report: When the Drugs Dont Work - Antibiotic Resistance as a Global Development Problem, by ReAct and the Dag Hammarskjöld Foundation. The (also attached) provides concrete examples of the impacts of antibiotic resistance across different Sustainable Development Goals. Antibiotic resistance would seriously jeopardise the achievement of several of the Sustainable Development Goals related to poverty, health, food production and hunger, economic growth, inequality and the environment.The report is intended to inform and stimulate discussions on how to further advance the implementation of:- 2030 Agenda for Sustainable Development,- Global Action Plan on Antimicrobial Resistance,- National Action plans on Antimicrobial Resistance, and- Work within all sectors that affect and are affected by antibiotic resistance.These discussions must lead to decisions and concrete action on this urgent challenge, for which solutions must build on a systems perspective across sectors. Antibiotic resistance is a consequence of systems failures and should therefore be seen and addressed through a systems perspective. To limit the effects of antibiotic resistance, it must be considered a critical sustainable development issue. To achieve progress to meet this challenge, political will and action is urgently needed.It is equally critical to meet the funding needs for tackling antibiotic resistance with adequate resources and capacities. Last December, ReAct and the Dag Hammarskjöld Foundation jointly organized a meeting as an early step in discussing options for concrete proposals on how to fund sustainable action on antibiotic resistance in line with needed functions at global and country levels. The discussion outcomes were summarized in a meeting report that is also attached. We invite you to lead further discussions around this critical topic on antibiotic resistance and sustainable development. We hope that the analyses and deliberations in both reports will stimulate further dialogues and lead to decisions and concrete action across sectors. Your feedback and comments are most welcome and we look forward to continuing the active engagement and moving forward action on antibiotic resistance.Sincerely, Anna Zorzet, MSc, PhD Head of ReAct Europe ReAct - Action on Antibiotic Resistance Uppsala University, Box 256, 751 05 Uppsala, Sweden Phone: +46 (0)18 471 66 76 E-mail: Website: www.reactgroup.org Facebook: Twitter: @reactgroup När du har kontakt med oss på Uppsala universitet med e-post så innebär det att vi behandlar dina personuppgifter. För att läsa mer om hur vi gör det kan du läsa här: http://www.uu.se/om-uu/dataskydd-personuppgifter/ E- mailing Uppsala University means that we will process your personal data. For more information on how this is performed, please read here: http://www.uu.se/en/about-uu/data-protection-policy
Allikas: Sotsiaalministeerium dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel